0001209191-20-050486.txt : 20200915
0001209191-20-050486.hdr.sgml : 20200915
20200915165120
ACCESSION NUMBER: 0001209191-20-050486
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200915
DATE AS OF CHANGE: 20200915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Evans Ronald M
CENTRAL INDEX KEY: 0001823355
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39512
FILM NUMBER: 201176500
MAIL ADDRESS:
STREET 1: C/O METACRINE, INC.
STREET 2: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Metacrine, Inc.
CENTRAL INDEX KEY: 0001634379
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472297384
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-369-7800
MAIL ADDRESS:
STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-15
0
0001634379
Metacrine, Inc.
MTCR
0001823355
Evans Ronald M
C/O METACRINE, INC.
3985 SORRENTO VALLEY BLVD., SUITE C
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
424693
D
Series A Convertible Preferred Stock
Common Stock
9803
I
By trust
Stock Option (Right to Buy)
6.63
2030-05-23
Common Stock
11764
D
Every 5.1 shares of Series A Convertible Preferred Stock (the "Preferred Stock") are convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
Evans Potter Rev. Trust 12/29/1989
The shares subject to the stock option shall vest in 36 equal monthly installments from the Vesting Commencement Date of May 24, 2020.
/s/ Catherine C. Lee, Attorney-in-fact
2020-09-15
EX-24.3_937148
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned's hereby makes,
constitutes and appoints Catherine C. Lee, and Josh Beroth of Metacrine,
Inc. signing individually, the undersigned's true and lawful attorney-in fact
and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 3rd day of September, 2020.
/s/ Ronald M. Evans, Ph.D.